A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Angiokeratomas (LOTU)
← catalyst calendarNCT07552077 · readout ≤ 377 d
Sponsored by Palvella Therapeutics, Inc. (industry) · PVLA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
15estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Apr 2026 | estimated | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Angiokeratomas
Intervention
- Drug: PTX-022
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events
measured 3 months
Overall Angiokeratoma Investigator Global Assessment (AK-IGA)
measured 3 months
Overall Patient Global Impression of Change (PGI-C)
measured 3 months
Permalink · PVLA's whole pipeline · Catalyst calendar · Every registered study · What changed